Biotech-Driven Innovation in Drug Discovery: Strategic Models for Competitive Advantage in the Global Pharmaceutical Market

Mia Md Tofayel Gonee Manik
Department of Biochemistry & Molecular Biology, University of Dhaka
Dhaka -1000, Bangladesh
Email: miatofayelgonee@gmail.com

***Abstract*—Biotechnology has significantly advanced modern drug discovery by enabling targeted, data-driven, and mechanism-based approaches. This paper explores how innovations such as high-throughput screening (HTS), molecular biology tools, synthetic biology, and precision medicine are transforming the discovery and development of therapeutic agents. Techniques like LC-MS, LC-NMR, and rational drug design offer deep insights into disease mechanisms and compound-target interactions. The identification and validation of drug targets have been enhanced through tools such as microarrays, RNA interference, and bioinformatics, while CRISPR-based genome editing allows precise genetic modifications. AI and ML help find new drugs by making new compounds, predicting how drugs will interact with their targets, and making clinical study designs better. Despite these advancements, challenges persist in drug solubility, central nervous system (CNS) drug delivery, bioavailability, and cost-effective large-scale production. Formulation strategies such as nanocrystals, lipid carriers, and complexation methods are being explored to overcome these limitations. Additionally, big data analytics and systems biology are reshaping the way researchers understand disease pathways and therapeutic responses. The convergence of these biotechnological innovations presents unprecedented opportunities to accelerate drug development.**

***Keywords*—Biotechnology, Drug Discovery, Artificial Intelligence, Machine Learning, Biopharmaceuticals, Precision Medicine, Drug Development Challenges.**

I. INTRODUCTION

Biotechnology has emerged as a transformative discipline that applies biological systems and molecular technologies to develop innovative solutions across healthcare, agriculture, and industry. By enabling precise manipulation of genetic material and cellular mechanisms, biotechnology has revolutionized scientific research and product development, accelerating progress in understanding complex biological phenomena [1]. This foundational advancement sets the stage for new therapeutic approaches and medical breakthroughs that directly impact human health.

The high-risk, high-reward field of drug development necessitates a multidisciplinary approach in Biotechnology has profoundly influenced pharmaceutical development by enabling the creation of biopharmaceuticals drugs derived from living organisms that offer high specificity and targeted action. Unlike traditional chemical drugs, biologics like recombinant proteins, monoclonal antibodies, and gene therapies are made to change specific molecular pathways that cause illness. This makes treatment work better and has fewer side effects. This evolution in drug design is particularly critical for addressing diseases that were previously difficult to treat, such as autoimmune disorders, cancer, and genetic conditions [2].

The biotechnological advancements have a significantly greater worldwide influence than scientific discoveries. In addition to improving treatment results and addressing urgent healthcare issues, it has the potential to completely change the healthcare system to become more proactive, preventative, and patient-centered. This thorough research aims to explore the complex network of significant developments that characterize biotechnology's place in healthcare globally. This analysis looks at worldwide patterns in order to give a more nuanced picture of how biotechnological developments are affecting healthcare systems, regulations, and patient outcomes globally. The use of biotechnology into the drug discovery process has expedited early-stage medication development and sped up the identification of new targets. Techniques like recombinant DNA technology, gene editing, and high-throughput screening enable researchers to explore disease mechanisms more deeply and design compounds capable of interacting with multiple biological targets a concept known as polypharmacology. These advances increase the probability of clinical success by addressing the complexity of multifactorial diseases, marking a shift from traditional single-target drug paradigms [3]. For drug makers, "one drug, one target" is no longer the goal. Now, "one drug, many targets" is the objective. It's called polypharmacology.

Additionally, the convergence of biotechnology with AI and ML has redefined strategic innovation in the pharmaceutical sector. AI/ML algorithms analyse vast biological and chemical datasets to predict drug–target interactions, design novel compounds, and optimize clinical trial workflows [4][5]. These advanced computational tools complement biotechnological innovations, enabling pharmaceutical companies to reduce development timelines, enhance R&D efficiency, and gain a competitive edge in the global healthcare market.

A. Organization of the paper

This paper is arranged in this way The importance of biotechnology in drug discovery is talked about in Section II. Section III highlights AI and ML as key technological enablers. Section IV discusses challenges and limitations in biotech-driven drug development. Section V reviews recent advancements, and Section VI concludes with future research directions.

II. Role Of Biotechnology In Modern Drug Discovery

Current drug development techniques advance our knowledge of these illnesses by shedding light on the processes behind phytochemical activity against medication resistance. Recently, sophisticated analytical techniques that aid in the isolation, identification, and characterization of possible compounds have been used [6]. Moreover, hyphenated approaches like LC-MS and LC-NMR that combine separation and detection methods work well to make compound identification faster. This covers all of current drug discovery, as shown in Figure 1.



Fig. 1. Modern Drug discovery

Since molecular biology, biochemistry, and structural biology have come together, drug development has entered a new era. A modern strategy based on a thorough comprehension of the illness process as well as the structure and function of the target molecule is rational drug design. Researchers can create specific and effective treatment drugs that target specific interactions thanks to this inherent information. However, developing these drugs necessitates a thorough understanding of the illness and the characteristics of the targeted molecule. It is considered by many to be one of the most inventive methods in contemporary medicine. EGCG targets the β-lactamase enzymes, which cause bacteria to become resistant to antibiotics and efflux pumps.

A. Target Identification and Validation

The DD method needs to find and confirm treatment targets in order to lower the risk of failure in later stages of drug development. Knock-out and knock-in studies in mice or cells are usually used to study gene effects in cell-based or animal models. The tools for choosing targets and making sure they are correct are shown below in Figure 2.



Fig. 2. Tool of Target Identification and Validation

- **Microarrays:** Target discovery looks for new targets, which are usually proteins (or DNA/RNA) that can be changed to stop or reverse the progress of a disease [7]. Researchers can try to find new targets by connecting changes in how genes (genomics) and proteins (proteomics) are expressed with people's diseases.
- **Nucleic acid microarrays:** Nuclear-acid microarrays use DNA as array components. These include cDNAs that have been expanded by PCR (100–3000 base pairs), long oligonucleotides (50–120nt), and short oligonucleotides (15–25nt). The selection of targets for drug design has been greatly influenced by nucleic-acid microarrays, which have also greatly improved our knowledge of normal and aberrant cell biochemistry.
- **Protein microarrays:** Proteins are therapeutic targets, and drug development is expected to be significantly impacted by protein and peptide microarrays. Interactions between proteins and DNA [8]. using antibody arrays to find changes in protein expression and linking them to a disease profile, possible targets, and biomarkers for a certain disease.
- **Bioinformatics:** Bioinformatics is an important part of analysing high-throughput studies like DNA microarrays. It can help with target selection and validation by giving functional information about possible targets and where they are in biological networks.
- **RNA interference:** A new strategy that employs sequence-specific RNA to knock down genes, RNAi, has drawn much greater attention from the scientific community. Fas siRNA reduced the amount of Fas mRNA produced by eight to ten times.
- *Zinc finger proteins:* ZFP can target different parts of the genome because their C2H2 domains have different amino acid sequences. They are also very good at recognising different DNA patterns. This is the ZFP.
- **Chemical genomics and proteomics:** There is a way that forward chemical genetics looks for targets for known drugs instead of drugs looking for targets like the old pharmaceutical method does.

B. High-Throughput Screening (HTS) and Automation

HTS contributes significantly to the early phases of drug development by offering analytical assistance for preclinical and clinical ADME investigations as well as qualitative and quantitative characterization of chemical libraries [9][10]. HTS therefore helps to eliminate inappropriate compounds early. Additionally, in silico techniques are essential for drug discovery. High-throughput library screening, assay creation, reagent production, and target discovery are some of the processes that are used.

C. Biologics and Monoclonal Antibodies

Biologicals are things like viruses, therapeutic serums, toxins, antitoxins, vaccines, blood products, blood components or derivatives, allergenic products (or similar products), arsphenamine or its derivatives (or any other trivalent organic arsenic compound) used to stop, treat, or cure conditions or diseases in people.[11] Monoclonal antibodies, in particular, have revolutionized treatment strategies for cancers, autoimmune diseases, and chronic inflammatory conditions due to their high specificity and efficacy.

D. Synthetic Biology and Rational Drug Design

The discipline of DD is arguably being reoriented by SB, much like organic chemistry was at the forefront of pharmaceutical industry innovation a century ago. SB also uses protein engineering as a technique. An enzyme's area stereospecificity can be increased by site-directed mutagenesis, as show in Figure 3.



Fig. 3. Synthetic Biology Tools are Used at Different Stages of Drug Discovery

Biosynthetic units can be used to mix and match modules to learn more about the chemistry of nanoparticles. The lux operon [Lux] controls an enzyme-based process in bacteria that gives off light. Light can activate protein photosensors such as LOV (light, oxygen, or voltage) regions or GFP (green fluorescent protein) [12]. These biosensors can be used for many things, such as confirming drug targets, learning how the medicine works by simulating a disease, and starting a drug delivery system in a certain place or under certain conditions.

E. Personalized and Precision Medicine

Precision medicine is still based on using a lot of data, both about the people who are being treated and about the data itself. The data is mostly biology (e.g., transcriptomics, epigenomics, proteomics, metabolomics, pharmacogenomics, and genomics), and the goals are focused on each person. The goal of precision medicine is to find the best ways to treat each patient by looking at their unique biological traits and the group they are a part of.

III. Technological Enabler For Biotech Innovation

Technological advancements have played a pivotal role in accelerating innovation across the biotechnology landscape. From data-driven discovery platforms to next-generation genetic tools, these enablers empower biotech companies to design, develop, and deliver novel therapeutics with greater precision, speed, and scalability.

A. Artificial Intelligence and Data Analytics

A revolutionary age in healthcare is being ushered in by the combination of biotechnology, AI, and data analytics, which presents previously unheard-of possibilities for advancements in therapeutics, diagnostics, and precision medicine. In order to demonstrate the significant advantages in healthcare decision-making on a worldwide basis, this research investigates the synergy between biotechnology and AI, how data improves the interpretation of biotechnological data, and offers instances of effective integration.

1) Drug-Target Interaction Prediction

Drug targets are biological proteins that preferentially interact with chemical molecules in an effort to cure or diagnose a disease. The PubChem database is thought to have 35 million chemicals, including 130 protein groups like enzymes, that could be used to quickly find complex drug target relationships on a large scale [13]. Finding computational drug-target interactions could speed up the creation of new drugs and make medicine better for people. It would also help us learn more about complex biological interactions and important biological processes.

2) De Novo Molecule Generation Using Generative Models

De novo design allows researchers to rapidly explore vast and uncharted areas of chemical space, optimizing molecules for desired biological activity, physicochemical properties, and synthetic accessibility [14][15] Combined with **reinforcement learning** and **multi-objective optimization**, these generative models can be tuned to prioritize molecules with high effectiveness from scratch RNN, are frequently employed as generative models for sequential data and have shown effective in applications like NLP.

3) Optimizing clinical trial design

Only a few numbers of SAS analytical tools have traditionally been used during the clinical trial execution phase for data quality and transformation operations.

The clinical research process may benefit greatly from SAS analytical skills in a number of important areas, as seen in Figure 4 [16]. In contrast to SAS's conventional involvement in biostatistics activities, the operational operations usually take place considerably earlier in the process and involve little to no analytics-based decision-making.



Fig. 4. Clinical Trial Optimization Design

B. CRISPR cas9 Mediated Genome Editing Tools

The CRISPR (clustered regularly interspaced short palindromic repeats) system is shown in Figure 5. Streptococcus pyogenes and Staphylococcus epidermidis, two bacteria and archaea, contributed their defence systems to make it.



Fig. 5. CRISPR-Cas9 Mediated Genome Editing

Tools for CRISPR activation, interference, and genome editing. Editing the genome with CRISPR [17]. The Cas9 protein combines with sgRNA three or four nucleotides ahead of the PAM sequence. Then it binds to the genetic DNA target site, which makes a DSB. To fix DSB, you can use either NHEJ or HR. Random adds and takes aways are made to the genome in NHEJ

C. Bioinformatics and Big Data Analytics

In bioinformatics research, the amount of data is rapidly increasing. Search engine logs and indexes and particle physics experiments are no longer the exclusive sources of big data [18]. The four main categories of data that are utilized extensively in bioinformatics research are enormous in size:

- **Gene expression data:** In gene expression analysis, hundreds of genes' expression levels are examined under various circumstances, such as distinct phases of a disease or treatment's development.
- **Sequence analysis:** To comprehend the characteristics, roles, structures, and evolution of DNA, RNA, or peptide sequences, a variety of analytical techniques are applied. DNA sequencing is utilized in evolutionary biology, microspecies identification, the study of genomes and proteins and their relationships to illnesses and phenotypes, and the development of possible medications.
- **PPIs:** PPIs offer vital details about every biological function. Consequently, a proper knowledge of protein activities may be obtained through the formation and analysis of PPI networks. PPIs are the cause of a number of illnesses, including cancer and Alzheimer's disease. PPIs have been investigated in a variety of scientific domains, including molecular dynamics, biochemistry, bioinformatics, and quantum chemistry.
- **Gene ontology (GO)**: The GO database offers species-independent, dynamic, and organized gene ontologies for related molecular activities, cellular constituents, and biological processes. Controlled vocabularies are used by the GO database to enable querying at various levels.

IV. Challenges And Limitation In Biotech In Drug Discovery

There are a number of difficulties, but in general, one can distinguish between issues that are more directly associated to a molecule and issues that are frequently related to these medications:

A. Data Formulation Approaches for Improving Solubility

Incomplete absorption results from poor solubility, and early in the discovery process, solubility of compounds becomes an issue. [19] A number of advances in formulation science have led to workable ways to formulate medicines that don't dissolve well in order to improve delivery. There are many common ways to give drugs that don't dissolve, such as using nanosuspensions, cyclodextrin complexation, buffering or making salt, emulsion or microemulsion systems, stability, and surfactant solubilization.

B. Drug Delivery Strategies for Improving Efficacy of CNS Drugs

The number of patients with CNS illnesses is on the rise, very few medications are being licensed to treat them. CNS illnesses account for a startling 35% of the overall disease burden in Europe. According to reports, just 1% of CNS drug research efforts are focused on delivering chemicals to the brain, with the majority (99%) going towards discovering novel compounds.

C. Enhancement of Bioavailability

They can be made into solid-structured lipid nanoparticles (SLN or NLC), drug nanocrystals, or LDC nanoparticles to enhance the effectiveness of oral medications. All of these nanoparticles have 100% bioavailability because of their tiny size, which allows for intravenous injection. The business Nano Systems has demonstrated the use of pharmacological nanocrystals to increase oral bioavailability for a variety of medications.

D. Large Scale Production

The pharmaceutical industry offers large-scale production techniques that are both reasonably priced and compliant with regulations. Having a simple production technique alone is useless. In machine, a dissolver disc is used to make the pre-suspension (drug nanocrystals) or pre-emulsion (SLN, NLC, LDC) for the first empty container. [20]. After going through the homogenising head, the dispersion is moved to a second product container.

E. Molecular Phenotyping

In order to effectively utilize this genetic information, molecular phenotyping, which can do high-throughput transcriptome analysis as a secondary or even a main screen, shows promise as a method [21]. The significant difficulty to transfer such molecular hit detection has been a significant obstacle. Numerous studies have demonstrated that molecular phenotype gene signatures reliably provide a precise pathway-centric picture of the biological system.

F. Data Privacy and Ethical Use of Genomic Information

Data privacy issues are a significant ethical concern in biotech-driven drug discovery, particularly with the increasing use of genomic sequencing and AI-based diagnostics. Patients may not fully understand the extent to which their data will be used These issues underscore the need for robust data protection policies, transparent consent frameworks, and international regulations to ensure the ethical use of sensitive biological information.

V. LITERATURE REVIEW

A review of the literature is given in this section on the key technological and ethical challenges in biotechnology-driven drug discovery, with a summary presented in Table I.

Mohs and Greig (2017) drug development and discovery process, therefore facilitating the successful transfer of preclinical research to patients. The basic idea of our paper is that the process takes too long, is too hard, and costs too much. This means that any new drug that is finally approved for clinical use has to take into account a lot of biological targets, and for each new target, new research tools might be needed. It's possible that the development process would work better if research helped solve any of the many scientific and practical problems that come up during the process. By understanding these issues, early action can be taken to increase the chances of success [22].

In this paper Differding (2017) Indian companies' efforts to find and make new medicines from 1994 to the middle of 2016. To build it, pharmaceutical, biotechnology, and contract research businesses that only do NCE and R&D in India have to be found and carefully studied. A better understanding of India's drug discovery and development industry is gained by looking at the pipeline's general growth over the last 20 years, along with the roles played by business type, therapeutic focus, attrition rates, and licensing agreements to Western pharmaceutical pipelines [23].

In this paper Du et al., 2016, As a whole, this biology uses a mix of biology, chemistry, and computer programs to look at how genes, proteins, targets, chemicals, and other small molecules relate to and affect each other. Researchers in systems chemical biology can focus on new ways to find new drugs, such as drug target path finding. Biomedical researchers can use these techniques to find proof of genes linked to diseases and also to make new medicines that work. It could decide how a relationship will go based on an RDF semantic D-T network and goals connected to certain drugs (disease). An enhanced parallel random walk with restart technique is used to rank the potential targets. In addition to having strong scalability that makes them appropriate for large data analysis, the experimental tests demonstrate that the suggested techniques may effectively identify drug target connection path [24].

Nishamol and Gopakumar, 2015, As their understanding of complicated illnesses has grown, drug research has shifted from a one-target, one-drug approach to a new multi-target, multi-drug model for regulating numerous targets. In genome drug development, determining how pharmaceuticals interact with target proteins is crucial to finding novel therapies or new targets for already-approved medications. Owing to the time-consuming and expensive experimental procedure involved in predicting drug-target interactions, in silico prediction may be a productive method of offering valuable insights to bolster experimental interaction data [25].

Sakurai et al. (2014) biotech DDF has recently started working closely with traditional pharmaceutical companies to make new medicines. Their goal is to find and create new drugs. For the goal of coming up with a plan to help Biotech DDFs grow in Japan, they used commercial and public domain databases to look into 44 unlisted Biotech DDFs. Profiles and more research showed that most of the clinical compounds made by Japanese biotech DDFs that aren't mentioned are still in the development stage. This means that it's not likely that they will be approved as medicines [26].

Okuyama and Osada, 2013, Companies that worked with U-I were usually ones that didn't have a lot of experience with pharmaceutical research. Drug discovery has been a significant part of industrial innovation in the pharmaceutical sector. Compared to in-house drug development efforts, a larger proportion of U-I partnership programs used biologics. The allocation of specific illness applications showed that the absence of internal research capacity has been made up for by U-I partnership [27]

TABLE I. TERATURE REVIEW SUMMARY FOR BIOTECH DRIVEN IN DRUG DISCOVERY

Author (Year)	Methodology	Key Findings	Challenges / Limitations	Future Work
Mohs and Greig (2017)	Analytical overview of drug development phases	Drug development is long, complex, and expensive; multiple targets must be evaluated for successful translation to clinical use	High attrition rates; lack of effective tools to evaluate new targets	Improve research tools for early-stage screening and target validation

Differding (2017)	Longitudinal analysis of Indian pharmaceutical R&D pipelines (1994–2016)	Indian biotech and pharma companies contributed significantly through licensing; evolution of NCE pipelines detailed	High attrition in clinical trials limited success rates	Encourage collaboration and investment in proprietary drug development
Du et al. (2016)	Systems chemical biology with semantic RDF D-T network and random walk algorithm	Integration of chemical, biological, and computational tools enables discovery of drug-target pathways for efficient drug design	Need for high-performance computing and data integration	Scale up model for big data environments; refine algorithm for more accurate predictions
Nishamol and Gopakumar (2015)	Drug-target interactions predicted computationally	Shift toward multi-target drug models; in silico methods offer cost-effective alternatives to experimental screening	Prediction accuracy and validation remain challenges	Develop hybrid models combining in silico and experimental approaches
Sakurai et al. (2014)	Profiling of 44 Japanese unlisted Biotech DDFs using public and commercial data	Most Biotech DDFs in Japan are in early development stages; limited approval of compounds	Limited commercialization; early-stage development risks	Policy support and targeted funding needed to promote biotech growth
Okuyama and Osada (2013)	Study of university-industry (U-I) collaborations in biotech drug development	U-I collaboration supports companies lacking in-house capabilities; biologics are a significant focus in U-I projects	Reliance on academia may reduce innovation autonomy	Strengthen U-I frameworks for sustained innovation and commercialization

VI. Conclusion

Biotechnological procedures have to be viable from an economic, technical, and scientific standpoint. Biotechnology has significantly transformed modern drug discovery, offering innovative tools and strategies for identifying, validating, and optimizing therapeutic targets. The precision, effectiveness, and speed of drug discovery have increased with the integration of molecular biology, genomics, proteomics, and computational techniques like AI and ML. Techniques like RNA interference, CRISPR/Cas9, and protein microarrays have paved the way for highly specific treatments, while high-throughput screening and synthetic biology have accelerated compound identification and optimization. Despite these advancements, challenges persist, including poor drug solubility, limited delivery across the blood-brain barrier, poor bioavailability, and challenges with regulatory compliance and large-scale manufacturing.

Future work should focus on addressing these challenges through multidisciplinary methods and innovative technology. For the treatment of neurological illnesses, the creation of intelligent drug delivery systems—particularly those that can penetrate the blood-brain barrier—will be essential. Integrating real-time biosensors with AI can enhance dynamic process control in drug discovery and production. Additionally, the use of federated learning will support secure, collaborative research across institutions, preserving data privacy while enriching model robustness. Sustainable and scalable biomanufacturing methods, enabled by synthetic biology and automation, will be vital for meeting global healthcare demands.

References

[1] F. R. Vogenberg and C. Young, "Biotech injectable drugs: clinical applications and financial effects.," *Biotechnol. Healthc.*, vol. 1, no. 3, pp. 31–40, Jul. 2004.

[2] G. Orive, R. M. Hernández, A. R. Gascón, A. Domínguez-Gil, and J. L. Pedraz, "Drug delivery in biotechnology: present and future," *Curr. Opin. Biotechnol.*, vol. 14, no. 6, pp. 659–664, Dec. 2003, doi: 10.1016/j.copbio.2003.10.007.

[3] T. Balganesh, T. K. Kundu, T. K. Chakraborty, and S. Roy, "Drug discovery research in India: Current state and future prospects," *ACS Med. Chem. Lett.*, vol. 5, no. 7, pp. 724–726, 2014, doi: 10.1021/ml500183c.

[4] H. Ding, I. Takigawa, H. Mamitsuka, and S. Zhu, "Similarity-based machine learning methods for predicting drug–target interactions: a brief review," *Brief. Bioinform.*, vol. 15, no. 5, pp. 734–747, 2013, doi: 10.1093/bib/bbt056.

[5] V. Kolluri, "A Comprehensive Analysis On Explainable And Ethical Machine: Demystifying Advances In Artificial Intelligence," *TIJER - Int. Res. Journals*, vol. 2, no. 7, pp. 2349–9249, 2015.

[6] J. Silber, A. Kramer, A. Labes, and D. Tasdemir, "From Discovery to Production: Biotechnology of Marine Fungi for the Production of New Antibiotics," *Mar. Drugs*, vol. 14, no. 7, 2016, doi: 10.3390/md14070137.

[7] S. Wang, T. B. Sim, Y. S. Kim, and Y. T. Chang, "Tools for target identification and validation," *Curr. Opin. Chem. Biol.*, vol. 8, no. 4, pp. 371–377, 2004, doi: 10.1016/j.cbpa.2004.06.001.

[8] C. Smith, "Drug target validation: Hitting the target," *Nature*, vol. 422, no. 6929, pp. 342–345, 2003, doi: 10.1038/422341a.

[9] P. Szymański, M. Markowicz, and E. Mikiciuk-Olasik, "Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests," *Int. J. Mol. Sci.*, vol. 13, no. 1, pp. 427–452, Dec. 2011, doi: 10.3390/ijms13010427.

[10] V. Kolluri, "An Innovative Study Exploring Revolutionizing Healthcare With AI: Personalized Medicine: Predictive Diagnostic Techniques and Individualized Treatment," *JETIR - Int. J. Emerg. Technol. Innov. Res. (www. jetir. org| UGC issn Approv. ISSN*, vol. 3, no. 11, pp. 2349–5162, 2016.

[11] L. Zhao, T. Ren, and D. D. Wang, "Clinical pharmacology considerations in biologics development," *Acta Pharmacol. Sin.*, vol. 33, no. 11, pp. 1339–1347, Nov. 2012, doi: 10.1038/aps.2012.51.

[12] J.-Y. Trosset and P. Carbonell, "Synthetic biology for pharmaceutical drug discovery.," *Drug Des. Devel. Ther.*, vol. 9, pp. 6285–6302, 2015, doi: 10.2147/DDDT.S58049.

[13] X. Chen *et al.*, "Drug-target interaction prediction: Databases, web servers and computational models," *Brief. Bioinform.*, vol. 17, no. 4, pp. 696–712, 2016, doi: 10.1093/bib/bbv066.

[14] M. Olivecrona, T. Blaschke, O. Engkvist, and H. Chen, "Molecular De Novo Design through Deep Reinforcement Learning," *J. Cheminform.*, vol. 9, 2017, doi: 10.1186/s13321-017-0235-x.

[15] A. O. Badheka *et al.*, "ST-T wave abnormality in lead avr and reclassification of cardiovascular risk (from the national health and nutrition examination survey-III)," *Am. J. Cardiol.*, 2013, doi: 10.1016/j.amjcard.2013.04.058.

[16] D. Handelsman, "Optimizing Clinical Research Operations with Business Analytics," *SAS Glob. Forum Proc.*, p. 204, 2011.

[17] P. Tian, J. Wang, X. Shen, J. F. Rey, Q. Yuan, and Y. Yan, "Fundamental CRISPR-Cas9 tools and current applications in microbial systems," 2017. doi: 10.1016/j.synbio.2017.08.006.

[18] H. Kashyap, H. A. Ahmed, N. Hoque, S. Roy, and D. K.

Bhattacharyya, “Big Data Analytics in Bioinformatics: A Machine Learning Perspective,” vol. 13, no. 9, pp. 1–20, 2015.

[19] S. Basavaraj and G. V. Betageri, “Can formulation and drug delivery reduce attrition during drug discovery and development review of feasibility, benefits and challenges,” *Acta Pharm. Sin. B*, vol. 4, no. 1, pp. 3–17, Feb. 2014, doi: 10.1016/j.apsb.2013.12.003.

[20] R. H. Muller and C. M. Keck, “Challenges and solutions for the delivery of biotech drugs a review of drug nanocrystal technology and lipid nanoparticles,” *J. Biotechnol.*, vol. 113, no. 1–3, Sep. 2004, doi: 10.1016/j.jbiotec.2004.06.007.

[21] J. G. Moffat, F. Vincent, J. A. Lee, J. Eder, and M. Prunotto, “Opportunities and challenges in phenotypic drug discovery: an industry perspective,” *Nat. Rev. Drug Discov.*, vol. 16, no. 8, pp. 531–543, Aug. 2017, doi: 10.1038/nrd.2017.111.

[22] R. C. Mohs and N. H. Greig, “Drug discovery and development: Role of basic biological research.,” *Alzheimer’s Dement. (New York, N. Y.)*, vol. 3, no. 4, pp. 651–657, Nov. 2017, doi: 10.1016/j.trci.2017.10.005.

[23] E. Differding, “The Drug Discovery and Development Industry in IndiaTwo Decades of Proprietary Small-Molecule R&D,” *ChemMedChem*, vol. 12, no. 11, pp. 786–818, Jun. 2017, doi: 10.1002/cmdc.201700043.

[24] F. Du, T. Li, Y. Shi, L. Song, and X. Gu, “Drug target path discovery on semantic biomedical big data,” in *2016 IEEE International Conference on Big Data (Big Data)*, 2016, pp. 3381–3386. doi: 10.1109/BigData.2016.7840998.

[25] P. H. Nishamol and G. Gopakumar, “Multi-target drug discovery using system polypharmacology-state of the art,” in *2015 IEEE International Conference on Signal Processing, Informatics, Communication and Energy Systems (SPICES)*, 2015, pp. 1–5. doi: 10.1109/SPICES.2015.7091430.

[26] M. Sakurai, H. I. Munisi, H. Kakihara, and S. Sengoku, “The current status and value creation of unlisted Biotech Drug Discovery/Development Firms (Biotech DDFs) in Japan: A holistic approach,” in *Proceedings of PICMET ’14 Conference: Portland International Center for Management of Engineering and Technology; Infrastructure and Service Integration*, 2014, pp. 3612–3620.

[27] R. Okuyama and H. Osada, “University-industry collaboration in drug discovery in Japan: An empirical analysis over thirty years,” in *2013 Proceedings of PICMET ’13: Technology Management in the IT-Driven Services (PICMET)*, 2013, pp. 2704–2710.